Compare BIO-TECHNE Corp (TECH) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.29. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| TECH | YINN | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.48 | $56.62 |
52-Week Low | $43.31 | $21.45 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
YINN, the Direxion Daily FTSE China Bull 3x ETF, is trading at $28.05, down 7.49% with a bearish technical signal. The leveraged ETF faces pressure from mixed Chinese economic policies and U.S.-China trade tensions. Recent news highlights China's AI investment plans and export controls, creating volatility. Technical indicators show strong bearish momentum with moving averages signaling sell pressure.
The outlook remains cautious due to YINN's leveraged structure amplifying risks amid geopolitical uncertainty. While China's tech sector shows IPO momentum, the fund's inherent decay and China's economic stabilization efforts present both opportunity and significant risk for investors seeking Chinese equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
